Drugs that contain Sumatriptan Succinate
1. List of Alsuma drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7811254 | MERIDIAN MEDCL | Autoinjector with needle depth adapter |
Aug, 2027
(4 years from now) | |
Market Authorisation Date: 29 June, 2010
Treatment: Acute treatment of migraine attacks, with or without aura, and the treatment of cluster headache episodes
Dosage: INJECTABLE;SUBCUTANEOUS
ALSUMA family patents
4
United States
1
Taiwan, Province of China
1
Canada
1
European Union
2. List of Onzetra Xsail drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8047202 | CURRAX | Nasal devices |
Jul, 2023
(3 months from now) | |
| US8327844 | CURRAX | Nasal delivery method |
Oct, 2023
(6 months from now) | |
| US9119932 | CURRAX | Nasal delivery device |
Apr, 2024
(1 year, 1 month from now) | |
| US7975690 | CURRAX | Nasal devices |
Aug, 2025
(2 years from now) | |
| US8590530 | CURRAX | Nasal delivery devices |
Sep, 2025
(2 years from now) | |
| US9108015 | CURRAX | Nasal delivery devices |
Sep, 2025
(2 years from now) | |
| US10124132 | CURRAX | Nasal delivery |
Mar, 2027
(3 years from now) | |
| US10398859 | CURRAX | Nasal delivery devices |
Dec, 2027
(4 years from now) | |
| US8875704 | CURRAX | Nasal administration |
Apr, 2028
(5 years from now) | |
| US10722667 | CURRAX | Nasal administration |
Dec, 2028
(5 years from now) | |
| US10076615 | CURRAX | Nasal delivery |
Jul, 2029
(6 years from now) | |
| US8550073 | CURRAX | Nasal delivery |
Oct, 2029
(6 years from now) | |
| US8899229 | CURRAX | Powder delivery devices |
Aug, 2030
(7 years from now) | |
| US9649456 | CURRAX | Nasal administration |
Oct, 2030
(7 years from now) | |
| US8978647 | CURRAX | Nasal delivery |
Dec, 2030
(7 years from now) | |
| US10478574 | CURRAX | Nasal administration |
Nov, 2033
(10 years from now) | |
| US10076614 | CURRAX | Nasal delivery devices |
Oct, 2034
(11 years from now) | |
Market Authorisation Date: 27 January, 2016
Treatment: Method of drug delivery via the nasal cavity; Acute treatment of migraine by delivering a powdered substance comprising sumatriptan via a breath-powered delivery device; Acute treatment of migraine; Treatment of migraine via delivery of sumatriptan via the nasal cavity; Method of delivering sumatriptan to a nasal cavity
Dosage: POWDER;NASAL
ONZETRA XSAIL family patents
67
United States
39
United Kingdom
26
European Union
19
Japan
16
Australia
12
Canada
11
Spain
11
China
10
IB
8
Poland
8
Denmark
6
New Zealand
6
Austria
6
Korea, Republic of
5
Germany
5
Russia
5
Mexico
4
Brazil
4
South Africa
3
Singapore
3
Hong Kong
2
Portugal
2
Norway
2
India
2
Slovenia
1
Turkey
1
Malaysia
1
Indonesia
1
Cyprus
1
Israel
3. List of Sumavel Dosepro drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8343130 | ENDO VENTURES LTD | Needleless injector |
Oct, 2022
(5 months ago) | |
| US8491524 | ENDO VENTURES LTD | Needleless injector drug capsule and a method for filling thereof |
Nov, 2022
(3 months ago) | |
| US8241244 | ENDO VENTURES LTD | Needleless injector drug capsule and a method for filling thereof |
Nov, 2022
(3 months ago) | |
| US8267903 | ENDO VENTURES LTD | Casing |
Mar, 2023
(2 days ago) | |
| US8118771 | ENDO VENTURES LTD | Needleless injector drug capsule and a method for filling thereof |
Aug, 2023
(4 months from now) | |
| US8241243 | ENDO VENTURES LTD | Needleless injector drug capsule and a method for filling thereof |
Aug, 2023
(4 months from now) | |
| US8287489 | ENDO VENTURES LTD | Device for readying a needle free injector for delivery |
Dec, 2024
(1 year, 8 months from now) | |
| US7901385 | ENDO VENTURES LTD | Casing |
Jul, 2026
(3 years from now) | |
| US7776007 | ENDO VENTURES LTD | Device for readying a needle free injector for delivery |
Nov, 2026
(3 years from now) | |
Market Authorisation Date: 15 July, 2009
Treatment: NA
Dosage: INJECTABLE;SUBCUTANEOUS
SUMAVEL DOSEPRO family patents
21
United States
5
United Kingdom
5
Japan
5
European Union
4
Canada
3
Germany
2
Australia
1
Austria
1
Spain
4. List of Zecuity drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6745071 | TEVA BRANDED PHARM | Iontophoretic drug delivery system |
Feb, 2023
(27 days ago) | |
| US7973058 | TEVA BRANDED PHARM | Transdermal methods and systems for the delivery of anti-migraine compounds |
Apr, 2027
(4 years from now) | |
| US8597272 | TEVA BRANDED PHARM | Pharmacokinetics of iontophoretic sumatriptan administration |
Apr, 2027
(4 years from now) | |
| US9427578 | TEVA BRANDED PHARM | Pharmacokinetics of iontophoretic sumatriptan administration |
Apr, 2027
(4 years from now) | |
| US8470853 | TEVA BRANDED PHARM | Transdermal methods and systems for the delivery of anti-migraine compounds |
Apr, 2027
(4 years from now) | |
| US8155737 | TEVA BRANDED PHARM | Pharmacokinetics of iontophoretic sumatriptan administration |
Apr, 2027
(4 years from now) | |
| US9272137 | TEVA BRANDED PHARM | Transdermal methods and systems for the delivery of anti-migraine compounds |
Sep, 2027
(4 years from now) | |
| US8366600 | TEVA BRANDED PHARM | Polyamine enhanced formulations for triptan compound iontophoresis |
Apr, 2029
(6 years from now) | |
| US8983594 | TEVA BRANDED PHARM | Electronic control of drug delivery system |
Nov, 2030
(7 years from now) | |
| US9327114 | TEVA BRANDED PHARM | User-activated self-contained co-packaged iontophoretic drug delivery system |
Oct, 2032
(9 years from now) | |
Market Authorisation Date: 17 January, 2013
Treatment: Method for treating acute migraine in adults, with or without aura, comprising iontophoretic transdermal delivery of sumatriptan or a salt thereof; Method for treating acute migraine in adults, with or without aura, comprising iontophoretic transdermal delivery of sumatriptan or a salt thereof, using a flowable hydrogel formulation
Dosage: SYSTEM;IONTOPHORESIS
ZECUITY family patents
24
United States
10
Japan
8
New Zealand
8
Australia
7
Canada
7
China
7
European Union
6
EA
5
Hong Kong
5
Mexico
3
Israel
3
South Africa
3
Spain
3
Brazil
5. List of Zembrace Symtouch drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11364224 | UPSHER SMITH LABS | Pharmaceutical composition for treating migraine |
Jan, 2036
(12 years from now) | |
| US10537554 | UPSHER SMITH LABS | Pharmaceutical composition for treating migraine |
Jan, 2036
(12 years from now) | |
Market Authorisation Date: 28 January, 2016
Treatment: Treatment of migraine
Dosage: SOLUTION;SUBCUTANEOUS
ZEMBRACE SYMTOUCH family patents
4
United States
1
India
1
Mexico
1
Canada
1
China
1
Brazil
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic